Application

15598942 · COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES

Filed 2017-05-18 · Abandoned The official file ↗ · Art unit 1642 · Examiner Laura B Goddard Typical · CPC A61K 9/0019 · Merrimack Pharmaceuticals, Inc. · Honigman LLP

Office actions

first was Non-final rejection

RCEs

no appeal

To first action

11.5 mo

to disposition 18.1 mo

Statutes raised

103 DP

1 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.